In 2024, Paladin generated revenues of $70 million excluding products that Paladin has stopped commercializing or is in the process of discontinuing. "The reunion of Paladin and Knight ...
Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback